Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Decreases Stock Holdings in IQVIA Holdings Inc. $IQV

by · The Cerbat Gem

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 39.6% in the third quarter, HoldingsChannel reports. The institutional investor owned 4,422 shares of the medical research company’s stock after selling 2,905 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in IQVIA were worth $840,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in IQV. Artisan Partners Limited Partnership purchased a new position in shares of IQVIA in the second quarter valued at about $515,772,000. Norges Bank bought a new stake in shares of IQVIA in the second quarter worth about $270,160,000. AQR Capital Management LLC increased its holdings in IQVIA by 130.2% during the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after purchasing an additional 879,701 shares during the period. Laurel Wealth Advisors LLC raised its position in IQVIA by 15,755.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock valued at $122,857,000 after purchasing an additional 774,681 shares during the last quarter. Finally, Nordea Investment Management AB lifted its holdings in IQVIA by 41.7% in the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after buying an additional 606,391 shares during the period. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the topic of several research analyst reports. BMO Capital Markets assumed coverage on IQVIA in a research note on Thursday, November 13th. They set an “outperform” rating and a $260.00 target price on the stock. TD Cowen cut shares of IQVIA from a “buy” rating to a “hold” rating and lifted their price target for the company from $206.00 to $215.00 in a report on Monday, November 3rd. Morgan Stanley upped their price objective on shares of IQVIA from $250.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. UBS Group raised their target price on shares of IQVIA from $250.00 to $280.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Mizuho set a $266.00 price target on shares of IQVIA in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $249.19.

View Our Latest Stock Report on IQV

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is currently owned by insiders.

IQVIA Trading Down 0.6%

NYSE IQV opened at $240.94 on Tuesday. The stock’s fifty day moving average price is $224.91 and its 200-day moving average price is $201.35. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The stock has a market cap of $41.03 billion, a P/E ratio of 33.05, a P/E/G ratio of 2.47 and a beta of 1.36. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04.

IQVIA (NYSE:IQV – Get Free Report) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. IQVIA’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

See Also

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).